S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:MKD

Molecular Data Competitors

$1.18
+0.03 (+2.61 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.11
Now: $1.18
$1.44
50-Day Range
$1.07
MA: $1.14
$1.56
52-Week Range
$0.57
Now: $1.18
$11.90
Volume16.62 million shs
Average Volume200,286 shs
Market Capitalization$135.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Molecular Data (NASDAQ:MKD) Vs. UXIN, NEWT, WTRH, OPRX, EEX, and LQDT

Should you be buying MKD stock or one of its competitors? Companies in the industry of "business services, not elsewhere classified" are considered alternatives and competitors to Molecular Data, including Uxin (UXIN), Newtek Business Services (NEWT), Waitr (WTRH), OptimizeRx (OPRX), Emerald (EEX), and Liquidity Services (LQDT).

Uxin (NASDAQ:UXIN) and Molecular Data (NASDAQ:MKD) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Institutional and Insider Ownership

22.7% of Uxin shares are owned by institutional investors. Comparatively, 15.3% of Molecular Data shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Uxin and Molecular Data's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Uxin$227.64 million2.11$-350,840,000.00($0.60)-2.73
Molecular Data$1.90 billion0.07$-27,800,000.00N/AN/A

Molecular Data has higher revenue and earnings than Uxin.

Profitability

This table compares Uxin and Molecular Data's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Uxin-325.79%-884.77%-71.78%
Molecular DataN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Uxin and Molecular Data, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Uxin0000N/A
Molecular Data0000N/A

Summary

Molecular Data beats Uxin on 5 of the 7 factors compared between the two stocks.

Newtek Business Services (NASDAQ:NEWT) and Molecular Data (NASDAQ:MKD) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Profitability

This table compares Newtek Business Services and Molecular Data's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Newtek Business Services32.87%15.12%6.18%
Molecular DataN/AN/AN/A

Institutional & Insider Ownership

14.6% of Newtek Business Services shares are owned by institutional investors. Comparatively, 15.3% of Molecular Data shares are owned by institutional investors. 6.3% of Newtek Business Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Newtek Business Services and Molecular Data, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Newtek Business Services02002.00
Molecular Data0000N/A

Newtek Business Services currently has a consensus price target of $16.00, suggesting a potential downside of 12.57%. Given Newtek Business Services' higher probable upside, research analysts plainly believe Newtek Business Services is more favorable than Molecular Data.

Earnings and Valuation

This table compares Newtek Business Services and Molecular Data's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Newtek Business Services$59.29 million6.72$41.13 million$2.337.85
Molecular Data$1.90 billion0.07$-27,800,000.00N/AN/A

Newtek Business Services has higher earnings, but lower revenue than Molecular Data.

Summary

Newtek Business Services beats Molecular Data on 7 of the 9 factors compared between the two stocks.

Molecular Data (NASDAQ:MKD) and Waitr (NASDAQ:WTRH) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Molecular Data and Waitr's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular DataN/AN/AN/A
Waitr-118.32%-95.68%-19.67%

Institutional & Insider Ownership

15.3% of Molecular Data shares are owned by institutional investors. Comparatively, 43.6% of Waitr shares are owned by institutional investors. 16.6% of Waitr shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Molecular Data and Waitr, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Data0000N/A
Waitr01302.75

Waitr has a consensus target price of $6.3333, suggesting a potential upside of 79.41%. Given Waitr's higher probable upside, analysts clearly believe Waitr is more favorable than Molecular Data.

Valuation & Earnings

This table compares Molecular Data and Waitr's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Data$1.90 billion0.07$-27,800,000.00N/AN/A
Waitr$191.68 million2.04$-291,310,000.00($1.15)-3.07

Molecular Data has higher revenue and earnings than Waitr.

Molecular Data (NASDAQ:MKD) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Profitability

This table compares Molecular Data and OptimizeRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular DataN/AN/AN/A
OptimizeRx-23.79%-14.44%-11.49%

Institutional and Insider Ownership

15.3% of Molecular Data shares are held by institutional investors. Comparatively, 58.3% of OptimizeRx shares are held by institutional investors. 8.1% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Molecular Data and OptimizeRx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Data0000N/A
OptimizeRx00403.00

OptimizeRx has a consensus target price of $33.3333, indicating a potential upside of 33.07%. Given OptimizeRx's higher possible upside, analysts clearly believe OptimizeRx is more favorable than Molecular Data.

Earnings and Valuation

This table compares Molecular Data and OptimizeRx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Data$1.90 billion0.07$-27,800,000.00N/AN/A
OptimizeRx$24.60 million15.39$-3,140,000.00($0.19)-131.84

OptimizeRx has lower revenue, but higher earnings than Molecular Data.

Summary

OptimizeRx beats Molecular Data on 6 of the 10 factors compared between the two stocks.

Molecular Data (NASDAQ:MKD) and Emerald (NYSE:EEX) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Profitability

This table compares Molecular Data and Emerald's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular DataN/AN/AN/A
Emerald-402.06%8.30%2.74%

Earnings and Valuation

This table compares Molecular Data and Emerald's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Data$1.90 billion0.07$-27,800,000.00N/AN/A
Emerald$360.90 million0.94$-50,000,000.00$0.855.60

Molecular Data has higher revenue and earnings than Emerald.

Analyst Ratings

This is a summary of current recommendations for Molecular Data and Emerald, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Data0000N/A
Emerald04102.20

Emerald has a consensus target price of $4.5460, indicating a potential downside of 4.50%. Given Emerald's higher possible upside, analysts clearly believe Emerald is more favorable than Molecular Data.

Institutional and Insider Ownership

15.3% of Molecular Data shares are held by institutional investors. Comparatively, 27.3% of Emerald shares are held by institutional investors. 0.8% of Emerald shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Emerald beats Molecular Data on 7 of the 10 factors compared between the two stocks.

Liquidity Services (NASDAQ:LQDT) and Molecular Data (NASDAQ:MKD) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Profitability

This table compares Liquidity Services and Molecular Data's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Liquidity Services-6.92%-7.13%-4.27%
Molecular DataN/AN/AN/A

Valuation & Earnings

This table compares Liquidity Services and Molecular Data's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liquidity Services$226.52 million1.49$-19,260,000.00($0.22)-45.00
Molecular Data$1.90 billion0.07$-27,800,000.00N/AN/A

Liquidity Services has higher earnings, but lower revenue than Molecular Data.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Liquidity Services and Molecular Data, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Liquidity Services00103.00
Molecular Data0000N/A

Liquidity Services currently has a consensus price target of $9.00, indicating a potential downside of 9.09%. Given Liquidity Services' higher possible upside, equities analysts plainly believe Liquidity Services is more favorable than Molecular Data.

Institutional and Insider Ownership

65.1% of Liquidity Services shares are held by institutional investors. Comparatively, 15.3% of Molecular Data shares are held by institutional investors. 21.8% of Liquidity Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Liquidity Services beats Molecular Data on 6 of the 10 factors compared between the two stocks.


Molecular Data Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
UXIN
Uxin
0.5$1.64+14.6%$481.42 million$227.64 million-0.95High Trading Volume
Unusual Options Activity
Newtek Business Services logo
NEWT
Newtek Business Services
1.6$18.30+0.2%$398.61 million$59.29 million12.28
WTRH
Waitr
1.9$3.53+1.1%$391.82 million$191.68 million-1.14Analyst Upgrade
OPRX
OptimizeRx
1.5$25.05+4.3%$378.48 million$24.60 million-53.30Analyst Downgrade
Emerald logo
EEX
Emerald
1.1$4.76+9.9%$340.06 million$360.90 million-0.52
Liquidity Services logo
LQDT
Liquidity Services
1.6$9.90+1.4%$337.05 million$226.52 million-23.02
RMNI
Rimini Street
2.0$4.17+1.9%$318.11 million$281.05 million-14.89
PRTH
Priority Technology
1.6$4.65+7.5%$312.57 million$371.85 million-11.34
PAYS
PaySign
1.5$5.00+1.0%$249.22 million$34.67 million45.46
Points International logo
PCOM
Points International
1.5$11.95+0.8%$158.06 million$401.18 million108.65
PFSweb logo
PFSW
PFSweb
1.4$6.92+1.2%$140.12 million$294.02 million-115.31
ServiceSource International logo
SREV
ServiceSource International
1.8$1.40+0.0%$135.23 million$216.13 million-7.00
KRKR
36Kr
1.3$3.45+0.0%$129.35 million$94.17 million-0.37Upcoming Earnings
High Trading Volume
Heavy News Reporting
DHI Group logo
DHX
DHI Group
2.1$1.95+0.5%$102.25 million$149.37 million-3.31
Marchex logo
MCHX
Marchex
1.6$2.18+0.0%$86.27 million$106.13 million-3.07
China Customer Relations Centers logo
CCRC
China Customer Relations Centers
0.5$4.63+8.6%$84.87 million$173.41 million0.00
Exela Technologies logo
XELA
Exela Technologies
0.8$0.39+5.1%$57.87 million$1.56 billion-0.12
Steel Connect logo
STCN
Steel Connect
0.6$0.88+10.2%$55.23 million$782.81 million-6.77High Trading Volume
ALJJ
ALJ Regional
0.8$1.07+1.9%$45.13 million$355 million-0.57
Cypress Environmental Partners logo
CELP
Cypress Environmental Partners
1.3$2.61+0.4%$31.87 million$401.65 million-37.28
BSQR
BSQUARE
0.6$1.48+2.7%$19.59 million$59.28 million-6.43
SGRP
SPAR Group
0.8$0.90+3.3%$19.00 million$252.88 million45.02
CREG
China Recycling Energy
0.5$4.94+10.3%$15.44 million$870,000.000.00
SilverSun Technologies logo
SSNT
SilverSun Technologies
0.6$3.04+2.0%$13.68 million$38.50 million0.00
NCTY
The9
0.5$3.61+6.9%$10.97 million$50,000.000.00High Trading Volume
Heavy News Reporting
ARTL
Artelo Biosciences
0.6$0.56+1.8%$8.54 millionN/A-0.45
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.